MedTrace Logo

Efficacy of Whole-body Electromyostimulation (WB-EMS) Training in Participants With Pre-diabetes

NCT06188481 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-12-24

No results posted yet for this study

Summary

The goal of this pilot study is to assess the efficacy of the intervention (WB-EMS Training) in a sedentary group of adults with pre-diabetes and to estimate the potential effect sizes.

The main goals and questions it aims to answer are:

* Efficacy WB-EMS training in sedentary adults with pre-diabetes,
* Has WB-EMS training positive effects on HbA1c and other biomarkers?

Researchers will compare the intervention group with two control groups to see if WB-EMS training has effects on pre-diabetes.

Conditions

  • Pre-diabetes

Interventions

OTHER

whole-body electromyostimulation training

The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.

OTHER

activity tracker

Participants wear the activity tracker on their wrist for the entire 16-week study period.

OTHER

evidence-based lifestyle education program

Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Mahdieh Shojaa, Dr. · University Hospital Tuebingen/ Institute of Health Sciences/ Population-Based Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2025-12-17
Completion
2025-12-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06188481 on ClinicalTrials.gov